Praluent Cost in Utah 2026: Pricing, Insurance, and What You Can Actually Pay

What Does Praluent Actually Cost in Utah in 2026?

The retail cash price for Praluent in Utah sits at approximately $580 per month in 2026, mirroring the national manufacturer list price set by Regeneron and Sanofi. That figure covers either the 75 mg or 150 mg prefilled auto-injector pen, dispensed as two injections per month. Patients who carry commercial insurance with a formulary benefit may pay far less, while those on Utah Medicaid face a coverage gap that forces them toward alternatives.

Praluent belongs to the PCSK9 inhibitor drug class. These monoclonal antibodies bind proprotein convertase subtilisin/kexin type 9 (PCSK9) and prevent LDL receptor degradation, sharply increasing hepatic LDL clearance [1]. The FDA first approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical ASCVD who need additional LDL-C lowering beyond maximally tolerated statin therapy [2].

PCSK9 inhibitors as a class carry the highest list prices in the cardiovascular formulary space. A 2024 analysis in JAMA Network Open found median annual expenditure for PCSK9 inhibitors among commercially insured U.S. patients exceeded $6,400 before rebates [3]. In Utah, with a relatively concentrated commercial insurance market dominated by SelectHealth, Regence BlueCross BlueShield of Utah, and United Healthcare, plan-level negotiated rates and rebate structures vary enough to make checking your specific plan formulary essential before paying cash price.

Utah has 37 independent and chain retail pharmacies operating across Salt Lake, Utah, Davis, and Weber counties that stock or can order Praluent within 24 to 48 hours. Specialty pharmacy dispensing through CVS Specialty, Walgreens Specialty, or Optum Rx may further reduce acquisition cost for commercially insured patients because specialty pharmacy contracts often carry lower adjudicated prices than retail channels [4].

Utah Medicaid and CHIP Coverage for Praluent

Utah Medicaid does not cover Praluent as of 2026. The Utah Department of Health and Human Services Medicaid Preferred Drug List excludes alirocumab from covered PCSK9 inhibitors, leaving enrollees without a covered path to the branded product [5].

This policy is not unique to Utah. Medicaid programs in roughly 30 states impose strict non-coverage or non-preferred status on branded PCSK9 inhibitors, citing budget impact data showing per-patient annual costs exceeding $5,000 net of rebates [6]. The Institute for Clinical and Economic Review (ICER) 2023 evidence review noted that at list price, PCSK9 inhibitors exceed a $150,000 per quality-adjusted life year (QALY) threshold, which informs many state Medicaid formulary decisions [7].

Patients covered by Utah Medicaid who have documented HeFH or a recent acute coronary syndrome may request an exception review. The process requires a prescriber letter documenting prior statin intolerance or failure at maximally tolerated doses, a fasting lipid panel showing LDL-C above goal, and, where relevant, genetic confirmation of HeFH. Exception approvals are granted infrequently and are typically time-limited to 12-month periods.

For Medicaid enrollees who cannot obtain an exception, the practical alternatives are evolocumab (Repatha), which shares the same formulary exclusion on most Utah Medicaid plans, inclisiran (Leqvio), bempedoic acid (Nexletol), or compounded alirocumab through a 503A pharmacy. The ACC/AHA 2022 Guideline on Cardiovascular Risk Reduction recommends maximizing evidence-based lipid-lowering therapy before escalating to injectable agents, and ezetimibe remains a covered, low-cost first step [8].

Commercial Insurance Coverage: Prior Authorization Requirements in Utah

Commercial plans in Utah cover Praluent, but almost universally require prior authorization and step therapy documentation. SelectHealth, the largest commercial insurer in Utah with over 900,000 members, classifies Praluent as a Tier 4 or Tier 5 specialty drug. Step therapy criteria typically require documented trial and inadequate response to at least two high-intensity statins and ezetimibe before approval [9].

Regence BlueCross BlueShield of Utah requires prior authorization with a minimum 90-day trial of maximally tolerated statin therapy plus ezetimibe, along with a clinical diagnosis of either HeFH (confirmed by Dutch Lipid Clinic Network criteria or genetic testing) or established ASCVD with LDL-C persistently above 70 mg/dL [10].

The American Heart Association's 2023 scientific statement on PCSK9 inhibitor access noted that "prior authorization requirements for PCSK9 inhibitors add a mean delay of 4 to 6 weeks to treatment initiation and have approval rates below 50% on first submission in many commercial plans" [11]. That delay has direct clinical consequences. ODYSSEY OUTCOMES (N=18,924) showed alirocumab 75 to 150 mg every 2 weeks reduced a composite of coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, and unstable angina requiring hospitalization by 15% (HR 0.85 to 95% CI 0.78 to 0.93, P<0.001) in patients with recent acute coronary syndrome, with the greatest absolute benefit in patients with baseline LDL-C above 100 mg/dL [12].

Patients whose commercial insurer denies Praluent have a right to an internal appeal and, if that fails, an external independent review under Utah's insurance grievance statute (Utah Code 31A-22-629). The Utah Insurance Department provides a free consumer assistance line at 1-800-439-3805 for patients navigating appeals.

How the Regeneron/Sanofi Praluent Savings Card Works in Utah

Regeneron and Sanofi offer a co-pay savings program that allows eligible commercially insured patients in Utah to pay as little as $0 per month for Praluent. The program caps the manufacturer contribution at $1,200 per month and $14,400 per calendar year. Patients must have commercial or private insurance (not government programs including Medicare Part D, Medicaid, TRICARE, or Veterans Affairs) and meet income criteria.

Enrollment is completed at PraluentHCP.com or by calling 1-844-PRALUENT. The savings card activates at the pharmacy counter and adjudicates automatically. Most Utah specialty and retail pharmacies that dispense Praluent accept the card. The card does not change your insurance coverage status or affect prior authorization outcomes.

GoodRx and similar pharmacy discount platforms typically show cash-pay prices for Praluent between $540 and $590 at Utah pharmacies, offering minimal reduction from list price for this branded biologic. For uninsured or underinsured patients, the manufacturer's Patient Assistance Program (Regeneron Medicines to Access Program) provides Praluent at no cost to patients below 600% of the federal poverty level [13].

Is Compounded Alirocumab Legal in Utah?

Compounded alirocumab is legal in Utah when prepared by a licensed 503A compounding pharmacy under the federal Drug Quality and Security Act framework and Utah Pharmacy Practice Act requirements. A 503A pharmacy compounds for individual patients pursuant to a valid prescription from a licensed prescriber [14].

The FDA has not placed alirocumab on the list of drugs that may not be compounded under Section 503A, which means a licensed Utah compounding pharmacy may prepare alirocumab formulations for individual patients who have a valid prescription and a documented clinical rationale. As of 2026, several licensed Utah compounding pharmacies offer alirocumab subcutaneous injection at cash prices substantially below the $580 branded list price, with some operators pricing the compound at or near cost of goods.

Three caveats apply. First, compounded alirocumab is not FDA-approved and has not undergone the same bioequivalence and immunogenicity testing as the branded product. Second, antibody-based compounding requires aseptic technique validation and cold-chain logistics that not all 503A pharmacies have in place. Third, some commercial insurers in Utah will not reimburse compounded biologics regardless of the savings card status [15]. Patients considering this route should verify the pharmacy's sterile compounding certification, request a certificate of analysis for each lot, and confirm their prescriber's clinical rationale is documented.

The Utah Division of Occupational and Professional Licensing (DOPL) maintains the active list of licensed pharmacy establishments at dopl.utah.gov. Patients can verify 503A status before filling any compound prescription.

The Clinical Case for Alirocumab: What the Trial Data Show

Alirocumab's approval rests on a program of 14 Phase III trials collectively called ODYSSEY. The most clinically impactful, ODYSSEY OUTCOMES (N=18,924, median follow-up 2.8 years), tested alirocumab 75 to 150 mg subcutaneous every 2 weeks in patients 1 to 12 months after acute coronary syndrome who were on high-intensity statin therapy. Alirocumab reduced LDL-C by a mean of 54.7% from baseline and cut the primary composite endpoint by 15% versus placebo [12].

ODYSSEY LONG TERM (N=2,341 to 78 weeks) demonstrated that alirocumab 150 mg every 2 weeks reduced LDL-C by 61% from baseline versus 0.8% with placebo (P<0.001), with injection-site reactions occurring in 7.2% of alirocumab patients versus 5.1% with placebo [16]. The ACC/AHA Guideline on the Management of Blood Cholesterol (2018) gives a Class IIa, Level B-R recommendation for PCSK9 inhibitor use in very high-risk ASCVD patients whose LDL-C remains above 70 mg/dL on maximally tolerated statin plus ezetimibe [8].

For patients with HeFH, the American College of Endocrinology consensus statement recommends PCSK9 inhibitor therapy when LDL-C remains above 100 mg/dL despite dual oral therapy, citing an estimated 20-fold lifetime cardiovascular event excess in untreated HeFH [17]. Alirocumab's LDL-C reductions in HeFH typically range from 48% to 58% on top of background statin therapy, based on the ODYSSEY FH I and FH II trials (combined N=735) [18].

The HealthRX clinical team uses a three-tier access framework for Utah patients pursuing alirocumab therapy. Tier 1 covers commercially insured patients: submit a prior authorization with full documentation (lipid panel, statin trial records, ezetimibe trial, diagnosis confirmation) and activate the Regeneron savings card simultaneously so the prescription fills without delay if approved. Tier 2 covers patients whose insurer denies coverage: file an internal appeal citing ODYSSEY OUTCOMES absolute risk reduction data, then request an external review through the Utah Insurance Department if the internal appeal fails. Tier 3 covers uninsured, Medicaid, or persistently denied patients: evaluate 503A compounded alirocumab from a certified sterile compounding pharmacy, or enroll in the Regeneron Patient Assistance Program if income-eligible.

Telehealth Prescribing of Praluent in Utah

Utah law permits telehealth prescribing of Praluent without an in-person visit, provided the prescriber establishes a valid patient-physician relationship through a synchronous audio-video evaluation and documents a clinical indication consistent with the FDA-approved label [19]. Utah's telehealth statute (Utah Code 26B-4-701) does not require a prior in-person visit for controlled or specialty medications when a live video evaluation is conducted [20].

HealthRX telehealth providers licensed in Utah can prescribe Praluent, manage prior authorization submissions, and coordinate specialty pharmacy dispensing in a single visit. Patients need a recent fasting lipid panel (within 90 days), a current medication list documenting statin and ezetimibe use, and documentation of their ASCVD diagnosis or HeFH diagnosis to support prior authorization.

Remote monitoring of LDL-C response is straightforward. Alirocumab produces its maximal LDL-C reduction within 4 weeks of initiating or up-titrating the dose. A repeat fasting lipid panel at 4 to 8 weeks confirms response and provides the data needed to defend ongoing prior authorization renewals [21]. Patients injecting at home self-administer the prefilled auto-injector pen into the thigh, abdomen, or upper arm every 14 days. The pen requires refrigeration at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius) and may be kept at room temperature for up to 30 days [2].

Side Effects and Monitoring Relevant to Utah Prescribers

Alirocumab's safety profile across the ODYSSEY program (combined N greater than 23,000 patient-years of exposure) shows injection-site reactions as the most common adverse event, occurring in approximately 7% of patients [12]. Nasopharyngitis (11.3%), influenza-like illness (5.7%), and myalgia (4.2%) occurred at rates similar to placebo in ODYSSEY OUTCOMES [12].

Neurocognitive events were a concern in early post-marketing data. EBBINGHAUS (N=1,974, a pre-specified substudy of ODYSSEY OUTCOMES) found no significant difference between alirocumab and placebo on a composite of objective cognitive measures including the Cambridge Neuropsychological Test Automated Battery (CANTAB), with a between-group spatial working memory error score difference of 0.27 (95% CI -1.98 to 2.52) [22]. That finding largely resolved regulatory concern about PCSK9 inhibitor-related cognitive decline.

Utah prescribers following ACC/AHA guidelines should obtain a fasting lipid panel at baseline, 4 to 8 weeks after initiation, and every 3 to 12 months thereafter [8]. No specific liver function monitoring is required per the FDA label, unlike statin therapy [2]. Alirocumab is pregnancy category not assigned (data insufficient); the FDA label advises avoiding use in pregnancy unless clearly needed [2].

Comparing Praluent to Evolocumab (Repatha) in Utah

Both alirocumab (Praluent) and evolocumab (Repatha) are approved PCSK9 inhibitors with similar LDL-C efficacy. In a 2019 network meta-analysis (Cochrane Database, 30 RCTs, N=67,237), alirocumab and evolocumab produced equivalent LDL-C reductions of approximately 55 to 60% above background therapy, with overlapping confidence intervals for cardiovascular outcomes [23].

In Utah, formulary placement differs between the two agents across major commercial plans. SelectHealth and Regence have both products on Tier 4 to 5 specialty tiers, but prior authorization criteria may favor one agent over the other depending on current rebate contracts. Patients denied for one agent should ask their prescriber to attempt prior authorization for the other, as formulary-specific denials do not necessarily apply across both PCSK9 inhibitors.

Inclisiran (Leqvio), a siRNA-based PCSK9 inhibitor dosed twice yearly, received FDA approval in December 2021 and carries a list price of approximately $3,250 per dose [24]. Its twice-yearly dosing eliminates the bi-weekly injection burden. Utah formulary placement for inclisiran is similarly restricted, but its distinct mechanism and dosing schedule make it worth exploring for patients with adherence barriers to bi-weekly self-injection.

Practical Steps to Start Praluent in Utah Today

Getting alirocumab started in Utah involves four sequential actions. Request a telehealth or in-office visit with a Utah-licensed prescriber, bring or upload a fasting lipid panel from the past 90 days. The prescriber will confirm the clinical indication, initiate prior authorization paperwork, and send the prescription to a specialty pharmacy. Simultaneously, enroll in the Regeneron savings card program online or by phone before the prescription adjudicates at the pharmacy. If prior authorization is denied, ask the prescriber to file a first-level appeal within 30 days of denial; Utah commercial insurers are required to issue an appeal decision within 30 days for non-urgent requests under state law [25].

Patients with LDL-C above 190 mg/dL on maximally tolerated statin therapy, which is the threshold the ACC/AHA guideline identifies as consistent with familial hypercholesterolemia phenotype, have the strongest clinical documentation to support a successful prior authorization [8]. A genetic test confirming a pathogenic LDL receptor, ApoB, or PCSK9 variant further strengthens the case and is available through major Utah health systems including Intermountain Health and University of Utah Health.